Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A cancer and leukemia group B study

Journal of Clinical Oncology

Volumn 26, Issue 28, 2008, Pages 4595-4602

  Paschka, Peter ^b   Marcucci, Guido ^b   Ruppert, Amy S ^b   Whitman, Susan P ^b   Mrózek, Krzysztof ^b   Maharry, Kati ^b   Langer, Christian ^b   Baldus, Claudia D ^b   Zhao, Weiqiang ^b   Powell, Bayard L ^b   Baer, Maria R ^b   Carroll, Andrew J ^b   Caligiuri, Michael A ^b   Kolitz, Jonathan E ^b   Larson, Richard A ^b   Bloomfield, Clara D ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLT3 LIGAND; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EXON; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; RISK ASSESSMENT; SURVIVAL RATE; WILD TYPE; WILMS TUMOR 1 GENE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENES, WILMS TUMOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 53749101166     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.2058     Document Type: Article

References (51)

1. Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002
2. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998
3. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/ Eastern Cooperative Oncology Group study. Blood 96:4075-4083, 2000
4. Mrózek K, Marcucci G, Paschka P, et al: Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? Blood 109:431-448, 2007
5. Marcucci G, Maharry K, Whitman SP, et al: High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 25:3337-3343, 2007
6. Call KM, Glaser T, Ito CY, et al: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60:509-520, 1990
7. Yang L, Han Y, Suarez Saiz F, et al: A tumor suppressor and oncogene: The WT1 story. Leukemia 21:868-876, 2007
8. Haber DA, Buckler AJ, Glaser T, et al: An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell 61:1257-1269, 1990
9. Ariyaratana S, Loeb DM: The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 14:1-17, 2007
10. Yamagami T, Sugiyama H, Inoue K, et al: Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis. Blood 87:2878-2884, 1996
11. Nishida S, Hosen N, Shirakata T, et al: AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood 107:3303-3312, 2006
12. Bergmann L, Miething C, Maurer U, et al: High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90:1217-1225, 1997
13. Barragán E, Cervera J, Bolufer P, et al: Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 89:926-933, 2004
14. Yanada M, Terakura S, Yokozawa T, et al: Multiplex real-time RT-PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia. Leuk Lymphoma 45:1803-1808, 2004
15. Weisser M, Kern W, Rauhut S, et al: Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19:1416-1423, 2005
16. Lapillonne H, Renneville A, Auvrignon A, et al: High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 24:1507-1515, 2006
17. Rodrigues PC, Oliveira SN, Viana MB, et al: Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia. Pediatr Blood Cancer 49:133-138, 2007
18. Little M, Wells C: A clinical overview of WT1 gene mutations. Hum Mutat 9:209-225, 1997
19. Brown KW, Malik KTA: The molecular biology of Wilms tumour. Expert Rev Mol Med 3:1-16, 2001
20. Scott RH, Stiller CA, Walker L, et al: Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet 43:705-715, 2006
21. Mori N, Okada M, Motoji T, et al: Mutation of the WT1 gene in myelodysplastic syndrome and acute myeloid leukaemia post myelodysplastic syndrome. Br J Haematol 105:844-845, 1999
22. Takahashi T, Yamamoto R, Tanaka K, et al: Mutation analysis of the WT1 gene in secondary leukemia. Leukemia 14:1316-1317, 2000
23. Hosoya N, Miyagawa K, Mitani K, et al: Mutation analysis of the WT1 gene in myelodysplastic syndromes. Jpn J Cancer Res 89:821-824, 1998
24. King-Underwood L, Pritchard-Jones K: Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 91:2961-2968, 1998
25. Miyagawa K, Hayashi Y, Fukuda T, et al: Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies. Genes Chromosomes Cancer 25:176-183, 1999
26. Summers K, Stevens J, Kakkas I, et al: Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 21:550-551, 2007
27. Kolitz JE, George SL, Dodge RK, et al: Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of Cancer and Leukemia Group B study 9621. J Clin Oncol 22:4290-4301, 2004
28. Kolitz JE, George SL, Marcucci G, et al: A randomized comparison of induction therapy for untreated acute myeloid leukemia (AML) in patients < 60 years using P-glycoprotein (Pgp) modulation with valspodar (PSC833): Preliminary results of Cancer and Leukemia Group B study 19808. Blood 106:122a, 2005 (abstr 407)
29. Ruf RG, Schultheiss M, Lichtenberger A, et al: Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. Kidney Int 66:564-570, 2004
30. Aucella F, Bisceglia L, De Bonis P, et al: WT1 mutations in nephrotic syndrome revisited: High prevalence in young girls, associations and renal phenotypes. Pediatr Nephrol 21:1393-1398, 2006
31. Frueh FW, Noyer-Weidner M: The use of denaturing high-performance liquid chromatography (DHPLC) for the analysis of genetic variations: Impact for diagnostics and pharmacogenetics. Clin Chem Lab Med 41:452-461, 2003
32. Fröhling S, Schlenk RF, Breitruck J, et al: Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 100:4372-4380, 2002
33. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335, 2002
34. Yamamoto Y, Kiyoi H, Nakano Y, et al: Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97:2434-2439, 2001
35. Whitman SP, Ruppert AS, Radmacher MD, et al: FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 111:1552-1559, 2008
36. Caligiuri MA, Strout MP, Lawrence D, et al: Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58:55-59, 1998
37. Whitman SP, Liu S, Vukosavljevic T, et al: The MLL partial tandem duplication: Evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood 106:345-352, 2005
38. Döhner K, Schlenk RF, Habdank M, et al: Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106:3740-3746, 2005
39. Fröhling S, Schlenk RF, Stolze I, et al: CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-633, 2004
40. Marcucci G, Baldus CD, Ruppert AS, et al: Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study. J Clin Oncol 23:9234-9242, 2005
41. Baldus CD, Tanner SM, Ruppert AS, et al: BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B Study. Blood 102:1613-1618, 2003
42. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
43. Klein JP, Moeschberger ML: Survival Analysis: Techniques for Censored and Truncated Data. New York, NY, Springer-Verlag, 1997
44. Falini B, Mecucci C, Tiacci E, et al: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype [erratum appears in N Engl J Med 352:740, 2005]. N Engl J Med 352:254-266, 2005
45. Suzuki T, Kiyoi H, Ozeki K, et al: Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 106:2854-2861, 2005
46. Schnittger S, Schoch C, Kern W, et al: Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739, 2005
47. Thiede C, Koch S, Creutzig E, et al: Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107:4011-4020, 2006
48. Baldus CD, Thiede C, Soucek S, et al: BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: Prognostic implications. J Clin Oncol 24:790-797, 2006
49. Haber DA, Sohn RL, Buckler AJ, et al: Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci U S A 88:9618-9622, 1991
50. Stoll R, Lee BM, Debler EW, et al: Structure of the Wilms tumor suppressor protein zinc finger domain bound to DNA. J Mol Biol 372:1227-1245, 2007
51. Smith SI, Down M, Boyd AW, et al: Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice. Cancer Res 60:808-814, 2000